CA2786443C — Use of an adrenal hormone-modifying agent

USPTO Abstract

The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or --C(O)N(Ra)(Rb) wherein Ra and Rb are independently --(C1-C4) alkyl, or --(C1-C4) alkyl-(C5-C7) aryl, wherein each of Ra and Rb is optionally substituted by --(C1-C4) alkoxy; R1, R2, and R3, are independently hydrogen, halogen, cyano or --(C6-C10) aryl, wherein said --(C6-C10) aryl is optionally substituted by halogen, with the proviso that no more than one of R1, R2, and R3 is hydrogen; and R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.